Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Array Biopharma Inc (ARRY) Stock: Gaining Big On Clinical Data

Today is likely to be a very interesting day in the market following the Trump win. Nonetheless, Array Biopharma Inc (NASDAQ:ARRY) is skyrocketing, and for good reason. Today, we’ll talk about what we’re seeing from the stock, why, and what we can expect to see from ARRY ahead. So, let’s get right to it…

What We’re Seeing From ARRY

As mentioned above, Array Biopharma Inc (NASDAQ:ARRY) had an incredibly strong day on the market. In pre-market, the stock made its way well into the green and the gains continued throughout the day. ARRY is trading at $6.51 per share after a gain of $0.45 per share or 7.43% on Wednesday.

engineering, lab, chemistry, test, experiment, reagents, technician, protective, pharmaceutical, researching, medical, liquid, chemist, bio, laboratory, clinic, substance,

bogdanhoda/Shutterstock.com

Why The Gains Are Happening

As usual, when we noticed that ARRY was headed up, the CNA Finance team started to do some digging to see what was causing the move. It didn’t take long to dig the cause up. The gains are the result of new clinical data that’s been made available.

For some time now, Array Biopharma was testing a combination treatment including Binimetinib and encorafenib. Recently, we learned that the clinical study met its primary endpoint. ARRY showed statistically significant results in an advantage on median progression free survival rates of 14.9 months, compared to 7.3 months with the current standard of care.

What We Can Expect To See Ahead

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Array Biopharma Inc (NASDAQ:ARRY). At the end of the day, the company has proven that a treatment it is working on is effective. That means that the treatment will likely lead to great things ahead. All in all, I’m expecting to see gains!

Follow Array Biopharma Inc (NASDAQ:ARRY)
Trade (NASDAQ:ARRY) Now!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required


Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at CNAFinanceHelp@gmail.com!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...